Valneva's IXCHIQ shows 94% seroresponse five years after single dose
VALN•Valneva reported five-year study results showing a 94% seroresponse after a single dose of its chikungunya vaccine IXCHIQ. Older adults showed antibody persistence comparable to younger adults.
1. Five-year antibody results
Valneva reported sustained antibody responses five years after a single dose of IXCHIQ, with a 94% seroresponse. Older adults showed antibody persistence comparable to younger adults.
